Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer

Prostate Cancer and Prostatic Diseases

Volumn 15, Issue 4, 2012, Pages 346-352

  Colquhoun, A J ^a   Venier, N A ^a   Vandersluis, A D ^a   Besla, R ^a   Sugar, L M ^b   Kiss, A ^b   Fleshner, N E ^c   Pollak, M ^d   Klotz, L H ^a   Venkateswaran, V ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

bicalutamide; diabetes mellitus; drug therapy (combination); metformin; obesity; prostate neoplasm

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; CASPASE 3; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN X; SOMATOMEDIN C;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIANDROGEN THERAPY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INCIDENCE; CANCER MORTALITY; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; APOPTOSIS; CELL SURVIVAL; CYTOPROTECTION; DRUG SYNERGISM; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MICE; NITRILES; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS;

EID: 84869211078     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2012.16     Document Type: Article

References (30)

1. American Cancer Society. Cancer Facts and Figures 2010. American Cancer Society: Atlanta, 2010.
2. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-1555.
3. IARC. International Agency for Research in Cancer. Weight Control and Physical Activity. IARC press: Lyon, 2002.
4. MacInnis RJ, English DR, Haydon AM, Hooper JL, Gertig DM, Giles GG. Body size and composition and risk of rectal cancer (Australia). Cancer Causes Control 2006; 17: 1291-1297. (Pubitemid 44772830)
5. Freedland SJ, Platz EA, Presti Jr JC, Aronson WJ, Amling CL, Kane CJ et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 2006; 175: 500-504. (Pubitemid 43067337)
6. Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 1977-1983. (Pubitemid 44664277)
7. Littman AJ, White E, Kristal AR. Anthropometrics and prostate cancer risk. Am J Epidemiol 2007; 165: 1271-1279. (Pubitemid 47234324)
8. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007; 109: 675-684. (Pubitemid 46233228)
9. Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R et al. Association of diet-induced hyperinsulinaemia with accelerated of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 2007; 99: 1793-1800. (Pubitemid 351767208)
10. Feller S, Boering H, Pischon T. Body mass index, waist circumference, and the risk of type 2 diabetes mellitus. Dtsch Arztebl Int 2010; 107: 470-476.
11. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9: 88-107.
12. Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D'Agostino RB. Trends in the incidence of type 2 diabetes mellitus from the 1970 to the 1990s. The Framingham Heart Study. Circulation 2006; 113: 2914-2918. (Pubitemid 44297232)
13. Cusi K, Consoli A, DeFronza RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996; 81: 4059-4067. (Pubitemid 26380418)
14. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 2063-2069.
15. Kahn B, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005; 1: 15-25. (Pubitemid 43960587)
16. Sahra IB, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576-3586. (Pubitemid 351793803)
17. Zakikhani M, Dowling R, Fabtus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269-10273. (Pubitemid 44799743)
18. Zhuang Y, Mikimins WK. Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, regulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 2008; 3: 18-29.
19. Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr-Relat Cancer 2008; 15: 833-839.
20. Zakikhani M, Dowling RJO, Sonenberg N, Pollak M. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Rev 2008; 15: 369-375.
21. Gotlieb WH, Samuet J, Beuchamp M-C, Gu J, Lau S, Pollak MN et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 2008; 110: 246-250.
22. Cantrell LA, Zhou C, Mendivil A, Molloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation- implications for a novel treatment strategy. Gynecol Oncol 2010; 116: 92-98.
23. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst 1999; 91: 1869-1876.
24. Knudsen KE, Arden KC, Cavenee WK. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. J Biol Chem 1998; 273: 20213-20222. (Pubitemid 28377582)
25. McCrohan AM, Morrissey C, O'Keane, Mulligan N, Watson C, Smith J et al. Effects of the dual 5-alpha reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines. Cancer 2006; 106: 2743-2752.
26. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with ImageJ. Biophotonics International 2004; 11: 36-42.
27. Frid A, Sterner G, Londahl M, Wiklander C, Cato A, Vinge E et al. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function. Diabetes Care 2010; 33: 1291-1293.
28. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondriadependent apoptosis. Cell Mol Life Sci 2007; 64: 1290-1302. (Pubitemid 46791062)
29. Floyd MS, Teahan SJ, Fitzpatrick JM, Watson RW. Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines. Prostate Cancer Prostatic Dis 2009; 12: 25-33.
30. Hou M, Venier N, Sugar L, Musquera M, Pollak M, Kiss A et al. Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet. Biochem Biophys Res Commun 2010; 397: 537-542.